Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study

ObjectiveComparing the efficacy of transarterial chemoembolization (TACE) combined with lenvatinib plus tislelizumab (TLT) with TACE combined with lenvatinib (TL) for unresectable hepatocellular carcinoma, particularly in determining which patients can benefit more from the TLT treatment.MethodsFrom...

Повний опис

Бібліографічні деталі

Автори:	Yushan Zhao, Shuwei Wen, YaoQing Xue, Zhijun Dang, ZhiYu Nan, Dong Wang, Xiao Li, Duiping Feng, Yi Chen
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-10-01
Серія:	Frontiers in Immunology
Предмети:	TACE lenvatinib tislelizumab hepatocellular carcinoma overall survival
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1449663/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!